Showing 271-280 of 1743 results for "".
- Stem Cell Treatment Responses Fails to Reach Statistical Significance and Has High Placebo Response Ratehttps://practicalneurology.com/news/stem-cell-treatment-responses-fails-to-reach-statistical-significance-and-has-high-placebo-response-rate/2469434/In a phase 3 clinical trial (NCT03280056) of autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY), 34.7% of participants wi
- Cell Therapy for ALS Associated with Increased Survival at 5 Yearshttps://practicalneurology.com/news/cell-therapy-for-als-shows-promise-in-increasing-survival-at-five-years/2475217/Nine out of 10 people with amyotrophic lateral sclerosis (ALS) treated with NurOwn (autologous mesenchymal stem cells [MSC]–neurotrophic factors [NTF]; BrainStorm Cell Therapeutics, New York, NY) survived more than 5 years after symptom onset. These results from an analysis of survival data from
- Stem Cell Therapy Reduced Brain Atrophy in People with Mild Alzheimer Diseasehttps://practicalneurology.com/news/stem-cell-therapy-reduced-brain-atrophy-in-people-with-mild-alzheimer-disease/2473818/The intravenous (IV) treatment of people with mild Alzheimer disease (AD) using Lomecel-B (laromestrocel; Longeveron, Miami, FL), a bone-marrow–derived allogeneic mesenchymal stem cell (MSC), was associated with reduced atrophy of the whole brain and hippocampus compared with placebo. These
- FDA Issues Refusal To File Letter for New Biologics License Application for Stem Cell ALS Treatmenthttps://practicalneurology.com/news/fda-does-not-file-new-biologics-license-application-for-stem-cell-amyotrophic-lateral-sclerosis-treatment/2470068/The Food and Drug Administration (FDA) has issued a refusal to file letter for the Biologics License Application (BLA) for autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY) as treatment of amyotrophic lateral sclerosis (A
- Phase 2 Clinical Trial for Stem-Cell Treatment of Alzheimer Disease Plannedhttps://practicalneurology.com/news/phase-2-clinical-trial-for-stem-cell-treatment-of-alzheimer-disease-planned/2469305/A phase 2 clinical trial to evaluate the safety and efficacy of treatment in individuals with prodromal to mild Alzheimer disease (AD) is planned for the autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY). The program is be
- Catherine Chu, MD, to Lead Pediatric Neurology at Kennedy Krieger and Johns Hopkinshttps://practicalneurology.com/news/catherine-chu-md-to-lead-pediatric-neurology-at-kennedy-krieger-and-johns-hopkins/2475483/Catherine Chu, MD, MA, MMSc, has been named Vice President of Child Neurology of the Kennedy Krieger Institute and will also serve as Director of the Division of Pediatric Neurology and the John M. Freeman Pediatric Epilepsy Center at Johns Hopkins Children’s Center. According to a statement rele
- In Memoriam: Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANAhttps://practicalneurology.com/news/in-memoriam-martin-a-samuels-md-dsc-hon-faan-macp-frcp-fana/2470226/Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANA, the first named Miriam Sydney Joseph Distinguished Professor of Neurology at Harvard Medical School, passed away on June 6, 2023, at age 77.
- 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research Presented to Lars Lannfelt, MD, PhDhttps://practicalneurology.com/news/2024-lifetime-achievement-award-in-alzheimers-disease-therapeutic-research-presented-to-lars-lannfelt-md-phd/2470618/Lars Lannfelt, MD, PhD has been recognized as the recipient of the 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. Dr. Lannfelt was selected based on his pioneering work in Alzheim
- UCSF Professor Bruce Ovbiagele, MD Recognized with Scientific Breakthrough Award at AAN 2024https://practicalneurology.com/news/ucsf-professor-bruce-ovbiagele-md-recognized-with-scientific-breakthrough-award-at-aan-2024/2470442/This year, the American Brain Foundation (ABF) awarded Bruce Ovbiagele, MD, MAS, FAAN the annual Scientific Breakthrough Award. Dr Ovbiagele, a Professor of Neurology at University of California (UC) San Francisco and Associate Dean of the San Francisco Veterans Affairs (VA) Healthcare Syste
- Possible Treatment for Focal Laryngeal Dystonia Revealed at MDS Conferencehttps://practicalneurology.com/news/possible-treatment-for-focal-laryngeal-dystonia-reported-at-mds-conference/2470597/Results of a double-blind, placebo-controlled, randomized cross-over study presented at the 2024 International Congress of Parkinson’s Disease and Movement Disorders suggest that sodium oxybate (SO) may be an effective treatment for some people with focal laryngeal dystonia (LD). This phase